Atlas Trials

Retrospective Chart Review and Historical Comparison of Capmatinib vs. Standard of Care for German Adult Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) Harboring METex14 Mutations

Clinical trial NCT05796726 · COMPLETED

Trial details

NCT number
NCT05796726
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
Locally Advanced or Metastatic Non-Small Cell Lung Cancer Harboring METex14 Mutations
Start date
2021-12-10
Primary completion
2022-03-22
Enrollment
260

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.